News - Inspiration Biopharmaceuticals, Women's Health

Filter

Popular Filters

1 to 25 of 95 results

Merck, Ferring and WHO working together to prevent excessive bleeding in women after childbirth

Merck, Ferring and WHO working together to prevent excessive bleeding in women after childbirth

06-04-2014

US pharma giant Merck & Co and privately-held Switzerland-headquartered Ferring Pharmaceuticals have…

carbetocinFerring PharmaceuticalsGlobalMarkets & MarketingMerck & CoPharmaceuticalResearchWomen's Health

GSK withdraws European marketing authorization for ovarian cancer drug Votrient

GSK withdraws European marketing authorization for ovarian cancer drug Votrient

31-03-2014

UK pharma major GlaxoSmithKline has withdrawn its application to the European Medicines Agency for a…

GlaxoSmithKlineOncologyPharmaceuticalRegulationUKVotrientWomen's Health

US FDA approves NDA from Actavis and Valeant

US FDA approves NDA from Actavis and Valeant

26-03-2014

US generics major Actavis and Canada’s Valeant Pharmaceuticals said that the US Food and Drug Administration…

ActavisCanadaGenericsMetronidazolePharmaceuticalRegulationUSAValeant PharmaceuticalsWomen's Health

Mike Sullivan appointed president of Avion Pharmaceuticals

Mike Sullivan appointed president of Avion Pharmaceuticals

18-03-2014

Avion Pharmaceuticals, a US-based specialty pharmaceutical company, has announced the promotion of Mike…

Avion PharmaceuticalsBoardroomNovartisPharmaceuticalReproductiveSanofiTher-RxUSAWomen's Health

Dilafor partners with Lee’s Pharmaceutical for tafoxiparin

24-02-2014

Sweden-based Dilafor AB, a Karolinska Development portfolio company, and Lee’s Pharmaceutical Holdings,…

Asia-PacificChinaDilafor ABKarolinska DevelopmentLee's PharmaceuticalLicensingPharmaceuticalReproductivetafoxiparinWomen's Health

Sprout Pharmaceuticals to resubmit NDA for flibanserin

Sprout Pharmaceuticals to resubmit NDA for flibanserin

12-02-2014

US privately-held sexual health specialists Sprout Pharmaceuticals has received ‘clear guidance’…

flibanserinPharmaceuticalRegulationSprout PharmaceuticalsUSAWomen's Health

European Commission approves Gedeon Richter’s Esmya type II Variation

European Commission approves Gedeon Richter’s Esmya type II Variation

27-01-2014

The European Commission has granted marketing authorization to extend the use of Esmya (ulipristal acetate)…

EsmyaEuropeGedeon RichterPharmaceuticalRegulationWomen's Health

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

23-01-2014

Indian biotech firm Biocon has entered into an exclusive licensing agreement for US cancer drug developer…

AdvaxisADXS-HPVAsia-PacificBioconIndiaLicensingOncologyPharmaceuticalWomen's Health

EMA pharmacovigilance unit calls for suspension of Protelos/Osseor

EMA pharmacovigilance unit calls for suspension of Protelos/Osseor

10-01-2014

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has recommended…

Anti-Arthritics/RheumaticsEuropeOsseorPharmaceuticalProtelosRegulationServierWomen's Health

Two Latin America acquisitions for Gedeon Richter

23-12-2013

In what was a busy couple of days for Hungary’s largest drugmaker Gedeon Richter, the company announced…

BrazilGedeon RichterMergers & AcquisitionsNext PharmaPharmaceuticalSouth AmericaWomen's Health

Torrent to acquire Indian branded formulations from Elder

13-12-2013

Torrent Pharmaceuticals saw its shares rise 7% to 349 rupees after it said it is acquiring the branded…

Asia-PacificElder PharmaceuticalsIndiaMergers & AcquisitionsNeurologicalPharmaceuticalTorrent PharmaceuticalsWomen's Health

Retrophin to acquire Kyalin Biosciences; in-licenses Syntocinon

13-12-2013

In a second takeover bid within a matter of months, USA-based Retrophin announced that it will acquire…

Kyalin BiosciencesLicensingMergers & AcquisitionsNeurologicalNorth AmericaNovartisPharmaceuticalRetrophinSyntocinonWomen's Health

No increase in risk of autism from taking SSRIs in pregnancy

25-11-2013

New research cannot establish a close connection between the use of antidepressant medication - the so-called…

NeurologicalPharmaceuticalResearchWomen's Health

Benefits of combined hormonal contraceptives continue to outweigh risks, says EMA/CHMP

Benefits of combined hormonal contraceptives continue to outweigh risks, says EMA/CHMP

23-11-2013

The European Medicines Agency has now completed its review of combined hormonal contraceptives (CHCs),…

EuropePharmaceuticalRegulationReproductiveWomen's Health

Merck’s new HPV vaccine could rejuvenate market, says GlobalData

Merck’s new HPV vaccine could rejuvenate market, says GlobalData

18-11-2013

Despite being hampered both by apathy and resistance in recent years, the human papillomavirus (HPV)…

CervarixGardasilGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalV503VaccinesWomen's Health

Ablynx and Eddingpharm sign deal to target Chinese osteoporosis market

Ablynx and Eddingpharm sign deal to target Chinese osteoporosis market

18-10-2013

Ablynx has granted an exclusive license to Eddingpharm to develop and commercialize its anti-RANKL Nanobody,…

AblynxAsia-PacificEddingpharmLicensingPharmaceuticalWomen's Health

Contraceptive benefits outweigh risks of blood clots, say EMA

Contraceptive benefits outweigh risks of blood clots, say EMA

14-10-2013

The European Medical Agency’s Pharmacovigilance Risk Assessment Committee has decided that the benefits…

EuropePharmaceuticalRegulationWomen's Health

FDA approves Bayer’s Adempas; firm accelerates drug candidates

FDA approves Bayer’s Adempas; firm accelerates drug candidates

09-10-2013

The US Food and Drug Administration late yesterday approved Adempas (riociguat), developed by German…

AdempasBayerCardio-vascularcopanlisibfinerenoneNorth AmericaOncologyPharmaceuticalRegulationResearchRespiratory and PulmonaryWomen's Health

US FDA backs Pfizer’s hot flashes drug Duavee

US FDA backs Pfizer’s hot flashes drug Duavee

04-10-2013

Pfizer and partner Ligand Pharmaceuticals say that the US Food and Drug Administration has approved Duavee,…

bazedoxifeneDuaveeLigand PharmaceuticalsNorth AmericaPfizerPharmaceuticalRegulationWomen's Health

Phebra gains right to market Syntometrine in Australia

Phebra gains right to market Syntometrine in Australia

27-09-2013

Phebra has signed an exclusive commercial agreement with UK-based pharmaceutical firm Alliance Pharma…

Alliance PharmaAsia-PacificLicensingPharmaceuticalSyntometrineWomen's Health

NICE recommends Genomic Health’s breast cancer test

NICE recommends Genomic Health’s breast cancer test

26-09-2013

Diagnostic testing provider Genomic Health has announced that the UK’s National Institute for Health…

BiotechnologyEuropeGenomic HealthOncologyRegulationWomen's Health

K-V Pharmaceutical emerges from bankruptcy with $375 million recapitalization

17-09-2013

USA-based K-V Pharmaceutical, which filed for bankruptcy in August 2012, when it was embroiled in controversy…

FinancialK-V PharmaceuticalPharmaceuticalWomen's Health

1 to 25 of 95 results

Company Spotlight

Fibrotech

Fibrotech

Back to top